<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059877</url>
  </required_header>
  <id_info>
    <org_study_id>QMF-MID12610</org_study_id>
    <nct_id>NCT01059877</nct_id>
  </id_info>
  <brief_title>Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia</brief_title>
  <official_title>Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quietmind Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maculume Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Quietmind Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will employ a double-blind, placebo-controlled approach to assess the effect of
      1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with
      early and mid-stage dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      What hypotheses are you testing?

      We are seeking to determine if the provision of brief, repeated exposure to 1072nm infrared
      stimulation of the cortex surface improves cognitive and behavioral functioning as indicated
      by normalization of EEG activity, increased cerebral oxygenation and demonstrated improvement
      on standardized neuropsychological measures.

      Intensive near infrared stimulation has been shown to be effective in accelerating healing of
      injuries and functional modification including increasing blood flow and perfusion. Dementia
      research has suggested that hypoperfusion is a significant underlying mechanism in the
      progression of dementia. Infrared spectroscopy has been shown effective in the non-invasive
      measurement of changes in cerebral oxygenation and perfusion. This study therefore seeks to
      explore whether the increasing of regional cerebral perfusion and oxygenation using infrared
      light stimulation will result in improved cognitive and behavioral functioning.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Small placebo controlled randomized trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) Delayed Word Recall.</measure>
    <time_frame>Post-tx (total intervention period = 28 days) scores to be compared to baseline scores.</time_frame>
    <description>Delayed Word Recall is a subscale of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog), a measure of cognitive impairment. Higher scores indicate greater impairment. Range: 0-10. Measures were taken within 72 hours of the first day of treatment and within 72 hours following the 28th day of treatment. Outcome measure was calculated by subtracting pretest from post test ADAS-Cog measurements.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>1072nm Infrared Photobiomodulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received treatment for dementia with transcranial 1072nm infrared light stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo device simulated transcranial photobiomodulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1072nm infrared Photobiomodulation</intervention_name>
    <description>1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.</description>
    <arm_group_label>1072nm Infrared Photobiomodulation</arm_group_label>
    <other_name>Photobiomodulation, Low-level LED Light Stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photobiomodulation SIMULATED</intervention_name>
    <description>Device mounted and procedure followed but with no stimulation.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 50 - 85 years.

          -  Have established cognitive impairment, Mini Mental Status Examination (MMSE) score
             between 15- 25 (from a possible score of 30).

          -  Generally healthy otherwise as indicated by recent physical examination.

          -  Have a caregiver/informant who has cared for the patient at least 5 days a week and is
             willing to attend study visits and provide information about the patient.

          -  If taking any psychotropic medication should have been stable for the previous 3
             months.

          -  Must have had B12, folic acid, full blood count and ferritin screen within the
             previous 6 months or be on B12 and/or folic acid replacement.

        Exclusion Criteria:

          -  Uncontrolled or unstable chronic illness, e.g., hypertension, chronic obstructive
             pulmonary disease (COPD).

          -  Diagnosed actively growing intracranial pathology (tumors etc).

          -  An associated psychotic illness.

          -  Misusing illegal substances or alcohol.

          -  On regular systemic steroids or anti-metabolites.

          -  Systemic malignancies and/or space occupying lesions in the brain.

          -  Not fluent in English.

          -  Depressed as assessed by Beck Depression Inventory score.

          -  Epilepsy.

          -  Lacking the capacity to give informed consent.

          -  Previous history of stroke or heart attack.

          -  History of aggression or violence.

          -  Inability to travel to the research venue for multiple assessments.

          -  A history of major psychiatric illness, seizure disorder, or physical illness that
             would compromise their participation in a daily treatment regimen.

          -  A participant may be disqualified if their performance is above the normative mean or
             below the lowest interpretable score of neuropsychological tests provided during the
             initial assessment (see #6, Sources of research material obtained from study
             participants, below).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marvin H Berman, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quietmind Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quietmind Foundation</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Berman MH, Halper JP, Nichols TW, Jarrett H, Lundy A, Huang JH. Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition. J Neurol Neurosci. 2017;8(1). pii: 176. doi: 10.21767/2171-6625.1000176. Epub 2017 Feb 28.</citation>
    <PMID>28593105</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <results_first_submitted>August 3, 2017</results_first_submitted>
  <results_first_submitted_qc>August 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2018</results_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Quietmind Foundation</investigator_affiliation>
    <investigator_full_name>Marvin H. Berman, Ph.D.</investigator_full_name>
    <investigator_title>clinical trial coordinator</investigator_title>
  </responsible_party>
  <keyword>dementia alzheimers frontotemporal lyme,</keyword>
  <keyword>lewy body cognitive impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>received actual tx</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>received placebo tx</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>received actual tx</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>received placebo tx</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" lower_limit="74" upper_limit="89"/>
                    <measurement group_id="B2" value="84" lower_limit="76" upper_limit="96"/>
                    <measurement group_id="B3" value="81" lower_limit="74" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Delayed word recall</title>
          <description>Delayed Word Recall is a subscale of the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog), a measure of cognitive impairment. Higher scores indicate greater impairment. Range: 0-10.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.50" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="B2" value="1.33" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="0.798" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trail making A</title>
          <description>The Trail Making Test (TMT) is used to investigate deficits in cognitive processing speed and executive function. Part A consists of 25 circles on a piece of paper with the numbers 1-25 in random order in the circles. The patient starts with number one and draws a line from that circle to the circle with number two, etc. to number 25. More errors indicate poorer performance.</description>
          <units>errors at task</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.83" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="B2" value="9.00" lower_limit="3" upper_limit="14"/>
                    <measurement group_id="B3" value="3.56" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) Delayed Word Recall.</title>
        <description>Delayed Word Recall is a subscale of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog), a measure of cognitive impairment. Higher scores indicate greater impairment. Range: 0-10. Measures were taken within 72 hours of the first day of treatment and within 72 hours following the 28th day of treatment. Outcome measure was calculated by subtracting pretest from post test ADAS-Cog measurements.</description>
        <time_frame>Post-tx (total intervention period = 28 days) scores to be compared to baseline scores.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>received actual tx</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>received placebo tx</description>
          </group>
        </group_list>
        <measure>
          <title>Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) Delayed Word Recall.</title>
          <description>Delayed Word Recall is a subscale of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog), a measure of cognitive impairment. Higher scores indicate greater impairment. Range: 0-10. Measures were taken within 72 hours of the first day of treatment and within 72 hours following the 28th day of treatment. Outcome measure was calculated by subtracting pretest from post test ADAS-Cog measurements.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="3" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Course of study, approx. 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>received actual tx</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>received placebo tx</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marvin Berman, PhD</name_or_title>
      <organization>QuietMind Foundation</organization>
      <phone>610.940.0488</phone>
      <email>marvinberman@quietmindfdn.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

